---
input_text: 'Posttransplant complications in patients with marrow failure syndromes:
  are we improving long-term outcomes? Inherited bone marrow failure syndromes (IBMFS)
  encompass a group of rare genetic disorders characterized by bone marrow failure,
  non-hematologic multisystemic comorbidities, disease defining congenital anomalies,
  and a susceptibility to myelodysplastic syndrome, acute myeloid leukemia, and in
  some instances solid tumors. The most common IBMFS include Fanconi anemia, Shwachman-Diamond
  syndrome, Diamond-Blackfan anemia, and telomere biology disorders/ dyskeratosis
  congenita. Allogeneic hematopoietic stem cell transplant (HCT) is a well-established
  curative treatment to correct the hematological manifestations but does not halt
  or reverse the nonhematological complications and may hasten them. With advances
  in HCT and in our ability to care for patients with IBMFS, an increasing number
  of survivors are making it imperative to not only diagnose but also treat late effects
  from the pre-, peri-, and post-HCT course and complications relating to the natural
  history of the syndrome. As the field of HCT evolves to allow for the incorporation
  of alternate graft sources, for expansion of donor options to include unrelated
  and mismatched donors, and for use of reduced-intensity conditioning or reduced
  toxicity myeloablative regimens, we have yet to determine if these advances modify
  the disease-specific course. While long-term outcomes of these patients are often
  included under one umbrella, this article seeks to address disease-specific post-HCT
  outcomes within IBMFS.'
raw_completion_output: |-
  primary_disease: Inherited bone marrow failure syndromes (IBMFS)

  medical_actions: Allogeneic hematopoietic stem cell transplant (HCT); Diagnosis; Treatment of late effects; Incorporation of alternate graft sources; Expansion of donor options; Use of reduced-intensity conditioning; Use of reduced toxicity myeloablative regimens

  symptoms: Bone marrow failure; Non-hematologic multisystemic comorbidities; Disease defining congenital anomalies; Susceptibility to myelodysplastic syndrome; Susceptibility to acute myeloid leukemia; Susceptibility to solid tumors

  chemicals: 

  action_annotation_relationships: Allogeneic hematopoietic stem cell transplant (HCT) TREATS bone marrow failure IN Inherited bone marrow failure syndromes (IBMFS); Diagnosis TREATS susceptibility to myelodysplastic syndrome IN Inherited bone marrow failure syndromes (IBMFS); Treatment of late effects TREATS non-hematologic multisystemic comorbidities IN Inherited bone marrow failure syndromes (IBMFS); Use of reduced-intensity conditioning PREVENTS non-hematologic multisystemic comorbidities IN Inherited bone marrow failure syndromes (IBMFS); Use of reduced toxicity myeloablative regimens PREVENTS non-hematologic multisystemic comorbidities IN Inherited bone marrow failure syndromes (IBMFS)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Use of reduced toxicity myeloablative regimens PREVENTS non-hematologic multisystemic comorbidities IN Inherited bone marrow failure syndromes (IBMFS)

  ===

extracted_object:
  primary_disease: Inherited bone marrow failure syndromes (IBMFS)
  medical_actions:
    - MAXO:0000149
    - Diagnosis
    - Treatment of late effects
    - Incorporation of alternate graft sources
    - Expansion of donor options
    - Use of reduced-intensity conditioning
    - Use of reduced toxicity myeloablative regimens
  symptoms:
    - HP:0005528
    - Non-hematologic multisystemic comorbidities
    - Disease defining congenital anomalies
    - Susceptibility to myelodysplastic syndrome
    - Susceptibility to acute myeloid leukemia
    - Susceptibility to solid tumors
  action_annotation_relationships:
    - subject: MAXO:0000149
      predicate: <TREATS>
      object: <bone marrow failure>
      qualifier: <Inherited bone marrow failure syndromes (IBMFS)>
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <hematopoietic stem cell transplant>
      object_extension: <bone marrow failure>
    - subject: <Diagnosis>
      predicate: <TREATS>
      object: <susceptibility to myelodysplastic syndrome>
      qualifier: <Inherited bone marrow failure syndromes (IBMFS)>
      subject_qualifier: <Not applicable>
      object_qualifier: <Not applicable>
      subject_extension: <Not applicable>
      object_extension: <Not applicable>
    - subject: <Treatment>
      predicate: <TREATS>
      object: <comorbidities>
      qualifier: <Inherited bone marrow failure syndromes (IBMFS)>
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <late effects>
      object_extension: <non-hematologic multisystemic>
    - subject: Use of reduced-intensity conditioning
      predicate: PREVENTS
      object: comorbidities
      qualifier: Inherited bone marrow failure syndromes (IBMFS)
      object_qualifier: non-hematologic multisystemic
      subject_extension: reduced-intensity conditioning
      object_extension: non-hematologic multisystemic
    - subject: <Use of reduced toxicity myeloablative regimens>
      predicate: <PREVENTS>
      object: <non-hematologic multisystemic comorbidities>
      qualifier: <Inherited bone marrow failure syndromes (IBMFS)>
      subject_extension: <reduced toxicity myeloablative regimens>
named_entities:
  - id: MONDO:0019391
    label: Fanconi anemia
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation (HSCT)
  - id: CHEBI:18198
    label: ADCs
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: CHEBI:37153
    label: Calcineurin inhibitor
  - id: CHEBI:38215
    label: Calcium channel blocker
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:8069
    label: Phenobarbital
  - id: CHEBI:2668
    label: Amlodipine
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MAXO:0000016
    label: Cellular therapy
  - id: HP:0001871
    label: Blood dyscrasias
  - id: MAXO:0000595
    label: Radiography
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0034057
    label: Congenital defects
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:44185
    label: Methotrexate
  - id: MONDO:0005233
    label: Non-small cell lung cancer (NSCLC)
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: HP:0002863
    label: Myelodysplasia
  - id: HP:0001909
    label: Leukemia
  - id: MONDO:0016624
    label: Hereditary anemia
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0005570
    label: Hematological disorders
  - id: HP:0002664
    label: cancer
  - id: MONDO:0015253
    label: Diamond Blackfan anemia
  - id: MAXO:0000600
    label: Kidney replacement therapy (KRT)
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003259
    label: Elevated serum creatinine (SCr > 100micromol/l)
  - id: MONDO:0001529
    label: Bone marrow failure (BMF)
  - id: HP:0002860
    label: oral squamous cell carcinoma (SCC)
  - id: MONDO:0100339
    label: Fanconi anemia (FA)
  - id: CHEBI:28680
    label: Ara-C
  - id: CHEBI:27899
    label: Cisplatin
  - id: HP:0011793
    label: Malignant tumors
  - id: HP:0000818
    label: Endocrinopathies
  - id: HP:0002745
    label: Oral leukoplakia
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:61049
    label: Tacrolimus
  - id: HP:0002910
    label: elevated liver function tests
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:231614
    label: Nivolumab
  - id: CHEBI:25016
    label: PBS
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:229764
    label: Selinexor
  - id: CHEBI:229762
    label: Eltanexor
  - id: HP:0006775
    label: Multiple Myeloma
  - id: CHEBI:229763
    label: exportin 1 inhibitors
  - id: MONDO:0015909
    label: aplastic anemia
  - id: HP:0004808
    label: Acute myeloid leukaemia
  - id: MAXO:0000004
    label: Surgery
  - id: MAXO:0000014
    label: Radiotherapy
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001945
    label: Fever
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome (PRES)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: MAXO:0001188
    label: Laparoscopy
  - id: HP:0000988
    label: Skin rash
  - id: MONDO:0010161
    label: Tyrosinemia Type 1
  - id: HP:0001919
    label: acute kidney injury (AKI)
  - id: HP:0000822
    label: hypertension
  - id: MAXO:0001298
    label: therapy
  - id: HP:0040012
    label: Increased chromosomal breakage
  - id: MONDO:0004631
    label: Tongue cancer (TC)
  - id: CHEBI:4735
    label: EDTA
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0025085
    label: Blood in stool
  - id: HP:0000568
    label: Microphthalmia
  - id: HP:0000482
    label: microcornea
  - id: HP:0000508
    label: ptosis
  - id: HP:0011496
    label: limbal neovascularization
  - id: HP:0001097
    label: keratoconjunctivitis sicca
  - id: CHEBI:62932
    label: Mycophenolate
